News and Announcements
Wholesale Investor Set to Take on New York and London
- Published August 25, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Wholesale Investor is pleased to announce that we are going to New York for the first time, bringing with us Australasia’s leading emerging growth companies for a special investor event co-hosted with DLA Piper, the New York Australasian Emerging Company Showcase on 27th of October 2017.
The New York event is part of our Australasian Emerging Company roadshow tour which also includes an investor event in London on 23rd of October 2017.
The international investor events, are part of our growing commitment to provide Australasia’s emerging companies and startups with access to international markets and high net worth investors from around the globe.
Wholesale Investor’s Managing Director, Steve Torso, spoke out about this new move. “We are excited about this new direction that Wholesale Investor is heading in. Across October and November, we are hosting 6 events, across 6 countries (Australia, UK, US, Singapore, Hong Kong and Korea) in 3 weeks! We are one of the first companies in this space to do this. As US & Asia close the gap in VC funding, it has never been a better time for companies seeking to raise capital or profile to investors, to tap into these markets.”
In 2017, Wholesale Investor has already hosted 25+ events across Australia, Singapore and UK with more than 4,800 investors registered, resulting in 3,200+ enquiries into client companies. Wholesale Investor has now crossed 17,200+ global investor network and 360+ clients.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
